Janssen Biotech Inc.

09/17/2019 | Press release | Distributed by Public on 09/17/2019 18:57

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)